Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET

Sex: Female

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 63

Sponsor: Centre Oscar Lambret

Summary

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients. Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy. The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 * Breast cancer treated by neo-adjuvant chemotherapy (T\>2cm) * Measurable lesions ,assessed clinically and by ultrasound * Delay minimum between biopsy and PET: 15 days * PS-WHO: 0 Exclusion Criteria: * T\1.40) * Pregnant or lactating women

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00904410). StuddyBuddy aggregates publicly available trial information.